Exenatide/insulin

Drug Profile

Exenatide/insulin

Alternative Names: ORMD 0801/ORMD 0901

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 27 Jun 2017 The Japanese Intellectual Property Office announces intention to grant Oramed Pharmaceuticals a patent for insulin/exenatide for treatment of Diabetes mellitus in Japan
  • 20 Apr 2017 Oramed Pharmaceuticals has patent protection for insulin/exenatide oral combination for Diabetes mellitus in Europe
  • 03 Jan 2013 Preclinical trials in Type-2 diabetes mellitus in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top